Table 1.

Trials of first-line EGFR-TKI therapy included in this study

Trial/Author	Patient selection	Drug	1st-line pts treated, n	1st-line pts tested for EGFR, n	1st-line pts tested for KRAS, n
Giaccone et al. (1)	Unselected	Erlotinib	53	28	26
Jackman et al. (2)	Patients ≥ age 70 y	Erlotinib	80	43	41
Miller et al. (3)	Adenocarcinoma with BAC features	Erlotinib	75	57	56
Sequist et al. (4)	Known EGFR mutations	Gefitinib	31	31	0
Jackman et al. (5)	Women, adenocarcinoma, not current smokers	Erlotinib	78	63	52

Abbreviations: pts, patients; BAC, bronchioloalveolar carcinoma.